Jeffrey C. Buchsbaum
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jeffrey C. Buchsbaum has a total of 282 co-authors. Here are the top co-authors by number of shared publications:
Ceferino Obcemea
National Cancer Institute Bethesda Maryland USA
7 shared publicationsPaige A. Taylor
The University of Texas MD Anderson Cancer Center, Houston, Texas
6 shared publicationsYing Xiao
Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania
6 shared publicationsHarald Paganetti
Department of Radiation Oncology, Massachusetts General Hospital & Harvard Medical School
5 shared publicationsBhadrasain Vikram
National Cancer Institute, Bethesda, MD
4 shared publicationsC. Norman Coleman
National Cancer Institute, Bethesda, Maryland 20892
4 shared publications
Latest Publications
- 17 May 2026
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 126 (4) , 910-922
Technical Considerations on Proton Therapy in NRG’s Multi-Institutional Clinical Trials
- 17 May 2026
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 126 (4) , 910-922
Technical Considerations on Proton Therapy in NRG’s Multi-Institutional Clinical Trials
- 24 March 2026
- Published by Cambridge University Press (CUP) in Disaster Medicine and Public Health Preparedness
- Vol. 20, e58
C. Norman Coleman’s Legacy in Radiation Research and Global Health: A Cancer Research and Care Perspective
Dr. C. Norman Coleman’s impact is difficult to measure overall, even if one focuses only on his work as NCI’s Radiation Research Program (RRP) leader. His laboratory work spanned immune-oncology and radiation therapy, RNA biology, normal tissue and tumor tissue radiobiology, and the development of tissue chips for use in radiation biology research. His programmatic leadership helped the RRP develop health equity programs addressing Native American access to optimal cancer care, evaluation of hadron therapy biology, radiation biology, reproducibility and rigor, foundational molecular biology of the tumor and normal tissue caused by radiation therapy dynamically, and global health and security issues. While doing all these things, he found time to mentor countless people in the field, many now leaders, and to read and discuss science across disciplines. He was a dedicated, caring, kind scientist who truly wanted to help and improve the world for others.
- 24 March 2026
- Published by Cambridge University Press (CUP) in Disaster Medicine and Public Health Preparedness
- Vol. 20, e58
C. Norman Coleman’s Legacy in Radiation Research and Global Health: A Cancer Research and Care Perspective
Dr. C. Norman Coleman’s impact is difficult to measure overall, even if one focuses only on his work as NCI’s Radiation Research Program (RRP) leader. His laboratory work spanned immune-oncology and radiation therapy, RNA biology, normal tissue and tumor tissue radiobiology, and the development of tissue chips for use in radiation biology research. His programmatic leadership helped the RRP develop health equity programs addressing Native American access to optimal cancer care, evaluation of hadron therapy biology, radiation biology, reproducibility and rigor, foundational molecular biology of the tumor and normal tissue caused by radiation therapy dynamically, and global health and security issues. While doing all these things, he found time to mentor countless people in the field, many now leaders, and to read and discuss science across disciplines. He was a dedicated, caring, kind scientist who truly wanted to help and improve the world for others.
- Top Cited Papers
- 2 February 2026
- Published by Elsevier in The Lancet Oncology
- Vol. 27 (2) , e101-e110
Reirradiation Collaborative Group (ReCOG) consensus on standards for dose evaluation and reporting in patients with multiple courses of radiation therapy: an AAPM/ACRO/ASTRO/CARO/COMP/CADRA/CPQR/ESTRO/NRG-endorsed consensus statement
- 2 February 2026
- Published by Elsevier in The Lancet Oncology
- Vol. 27 (2) , e101-e110
Top Cited PapersReirradiation Collaborative Group (ReCOG) consensus on standards for dose evaluation and reporting in patients with multiple courses of radiation therapy: an AAPM/ACRO/ASTRO/CARO/COMP/CADRA/CPQR/ESTRO/NRG-endorsed consensus statement
- 14 January 2026
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 124 (2) , 560
Erratum to Xiao Y, Benedict S, Cui Y, Glide-Hurst C, Graves S, Jia X, KryF S, Li H, Lin L, Matuszak M, Newpower M, Paganetti H, Qi XS, Roncali E, Rong Y, Sgouros G, Simone 2nd CB, Sunderland JJ, Taylor PA, Tchelebi L, Weldon M, Zou JW, Wuthrick EJ, Machtay M, Le QT, Buchsbaum JC. Embracing the future of clinical trials in radiation therapy: an NRG oncology CIRO technology retreat whitepaper on pioneering technologies and AI-driven solutions. Int J of Radiat Oncol Biol Phys 2025:122;443-457
- 14 January 2026
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 124 (2) , 560
Erratum to Xiao Y, Benedict S, Cui Y, Glide-Hurst C, Graves S, Jia X, KryF S, Li H, Lin L, Matuszak M, Newpower M, Paganetti H, Qi XS, Roncali E, Rong Y, Sgouros G, Simone 2nd CB, Sunderland JJ, Taylor PA, Tchelebi L, Weldon M, Zou JW, Wuthrick EJ, Machtay M, Le QT, Buchsbaum JC. Embracing the future of clinical trials in radiation therapy: an NRG oncology CIRO technology retreat whitepaper on pioneering technologies and AI-driven solutions. Int J of Radiat Oncol Biol Phys 2025:122;443-457
- 4 June 2025
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 24 (6) , 840-842
Three Articles from the NCI’s Preclinical Chemoradiotherapy Testing Consortium
In this issue of MCT, three articles from the NCI’s Preclinical Chemoradiotherapy Testing Consortium (PCRTC) are presented that each demonstrates a story of success. Each cooperative agreement team’s results are briefly summarized, and both the importance and the limitations of these studies are discussed. These preclinical studies used agents from the Cancer Therapy Evaluation Program portfolio to develop the foundation for translation into clinical trials. The structure of these studies was based on the prior work of the PCRTC that laid out the methodology for optimizing potential translation. Rigor and reproducibility have been a continuing focus of the PCRTC, with a key feature being the requirement for dose measurement and calibration to be traceable to national standards. Through the application of the consortium’s prior work establishing the standards for translation, each group generated promising data with high translational potential. See related article by Valvo et al., p. 843 See related article by Dragojevic et al., p. 859 See related article by Lu et al., p. 920
- 4 June 2025
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 24 (6) , 840-842
Three Articles from the NCI’s Preclinical Chemoradiotherapy Testing Consortium
In this issue of MCT, three articles from the NCI’s Preclinical Chemoradiotherapy Testing Consortium (PCRTC) are presented that each demonstrates a story of success. Each cooperative agreement team’s results are briefly summarized, and both the importance and the limitations of these studies are discussed. These preclinical studies used agents from the Cancer Therapy Evaluation Program portfolio to develop the foundation for translation into clinical trials. The structure of these studies was based on the prior work of the PCRTC that laid out the methodology for optimizing potential translation. Rigor and reproducibility have been a continuing focus of the PCRTC, with a key feature being the requirement for dose measurement and calibration to be traceable to national standards. Through the application of the consortium’s prior work establishing the standards for translation, each group generated promising data with high translational potential. See related article by Valvo et al., p. 843 See related article by Dragojevic et al., p. 859 See related article by Lu et al., p. 920
- Open Access
- 14 November 2024
- Published by MDPI AG in Tomography
- Vol. 10 (11) , 1798-1813
Conference Report: Review of Clinical Implementation of Advanced Quantitative Imaging Techniques for Personalized Radiotherapy
The topic of quantitative imaging in radiation therapy was presented as a “Masterclass” at the 2023 annual meeting of the American Society of Radiation Oncology (ASTRO). Dual-energy computed tomography (CT) and single-positron computed tomography were reviewed in detail as the first portion of the meeting session, with data showing utility in many aspects of radiation oncology including treatment planning and dose response. Positron emission tomography/CT scans evaluating the functional volume of lung tissue so as to provide optimal avoidance of healthy lungs were presented second. Advanced brain imaging was then discussed in the context of different forms of magnetic resonance scanning methods as the third area noted with significant discussion of ongoing research programs. Quantitative image analysis was presented to provide clinical utility for the analysis of patients with head and neck cancer. Finally, quality assurance was reviewed for different forms of quantitative imaging given the critical nature of imaging when numerical valuation, not just relative contrast, plays a crucial role in clinical process and decision-making. Conclusions and thoughts are shared in the conclusion, noting strong data supporting the use of quantitative imaging in radiation therapy going forward and that more studies are needed to move the field forward.
- 14 November 2024
- Published by MDPI AG in Tomography
- Vol. 10 (11) , 1798-1813
Open AccessConference Report: Review of Clinical Implementation of Advanced Quantitative Imaging Techniques for Personalized Radiotherapy
The topic of quantitative imaging in radiation therapy was presented as a “Masterclass” at the 2023 annual meeting of the American Society of Radiation Oncology (ASTRO). Dual-energy computed tomography (CT) and single-positron computed tomography were reviewed in detail as the first portion of the meeting session, with data showing utility in many aspects of radiation oncology including treatment planning and dose response. Positron emission tomography/CT scans evaluating the functional volume of lung tissue so as to provide optimal avoidance of healthy lungs were presented second. Advanced brain imaging was then discussed in the context of different forms of magnetic resonance scanning methods as the third area noted with significant discussion of ongoing research programs. Quantitative image analysis was presented to provide clinical utility for the analysis of patients with head and neck cancer. Finally, quality assurance was reviewed for different forms of quantitative imaging given the critical nature of imaging when numerical valuation, not just relative contrast, plays a crucial role in clinical process and decision-making. Conclusions and thoughts are shared in the conclusion, noting strong data supporting the use of quantitative imaging in radiation therapy going forward and that more studies are needed to move the field forward.
- 26 July 2024
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 121 (1) , 202-217
NRG Oncology White Paper on the Relative Biological Effectiveness in Proton Therapy
- 26 July 2024
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 121 (1) , 202-217
NRG Oncology White Paper on the Relative Biological Effectiveness in Proton Therapy
- 1 April 2024
- Published by Radiation Research Society in Radiation Research
- Vol. 201 (4) , 271-274
IN MEMORIAM1C. Norman Coleman, M.D. (1945–2024)
Radiation Research publishes work dealing with radiation effects and related subjects in the areas of physics, chemistry, biology and medicine.
- 1 April 2024
- Published by Radiation Research Society in Radiation Research
- Vol. 201 (4) , 271-274
IN MEMORIAM1C. Norman Coleman, M.D. (1945–2024)
Radiation Research publishes work dealing with radiation effects and related subjects in the areas of physics, chemistry, biology and medicine.
- 26 March 2024
- Published by Taylor & Francis in International Journal of Radiation Biology
- Vol. 100 (5) , 817-819
C. Norman Coleman, M.D. (1945–2024): mentorship, partnership, science, and kindness always
- 26 March 2024
- Published by Taylor & Francis in International Journal of Radiation Biology
- Vol. 100 (5) , 817-819
C. Norman Coleman, M.D. (1945–2024): mentorship, partnership, science, and kindness always